Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of blood and tissue from patients with basal cell nevus syndrome and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to basal cell nevus syndrome. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sirolimus may keep basal cell skin cancer from forming in patients with basal cell nevus syndrome.
PURPOSE: This phase I trial is studying topical sirolimus in patients with basal cell nevus syndrome and in healthy participants.
Non-Melanomatous Skin Cancer
Genetic: comparative genomic hybridization
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: protein expression analysis
Genetic: proteomic profiling
Other: laboratory biomarker analysis
Other: mass spectrometry
|Study Design:||Masking: Open Label
Primary Purpose: Prevention
|Official Title:||In Vivo and In Vitro Pharmacology of Sirolimus in Subjects With Basal Cell Nevus Syndrome|
- Alterations in RNA as measured by microarray analysis [ Designated as safety issue: No ]
- Alterations in protein expression as measured by 2-dimensional gel electrophoresis and matrix-assisted laser desorption ionization time-of-flight mass spectroscopy [ Designated as safety issue: No ]
- Compare messenger RNA and protein expression patterns in patients with basal cell nevus syndrome (BCNS) vs in cultured cells of healthy participants (control) before treatment to identify a set of genes that are differentially expressed in BCNS.
- Assess the effects of topical sirolimus on gene expression (genes identified in the primary objective) in vivo using keratinocytes, fibroblasts, and lymphocytes from patients with BCNS and from healthy participants (controls) by targeted expression methods.
OUTLINE: Patients and healthy participants receive topical sirolimus ointment twice daily for 12 weeks.
Blood and skin biopsies are obtained at baseline and at week 12 for gene and protein expression studies. Alterations in RNA are measured by microarray analysis. Alterations in protein expression are measured by 2-dimensional gel electrophoresis and matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
After completion of study therapy, patients and healthy participants are followed at 4 weeks.
PROJECTED ACCRUAL: A total of 16 patients and healthy participants will be accrued for this study.
|Principal Investigator:||Allen E. Bale, MD||Yale University|